Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
07:00am, Friday, 05'th Apr 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Associat
Natera: Capitalizing On The Positive Momentum Of Personalized Medicine
03:27pm, Friday, 22'nd Mar 2024
The global market size for personalized medicines is estimated to reach $1,233.23 billion by 2033, with North America experiencing significant growth in the oncology sector. Natera Inc., a diagnostic
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
07:00am, Monday, 18'th Mar 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
08:00am, Thursday, 14'th Mar 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chro
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residua
Final Trades: Natera, Disney, Chubb and ASML Holding
01:23pm, Monday, 11'th Mar 2024
The Investment Committee share their top stocks to watch for he second half.
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
08:00am, Thursday, 07'th Mar 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received commercial insurance coverage for its Prospera Heart
What Makes Natera (NTRA) a Strong Momentum Stock: Buy Now?
01:06pm, Monday, 04'th Mar 2024
Does Natera (NTRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript
09:30pm, Wednesday, 28'th Feb 2024
Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript
Compared to Estimates, Natera (NTRA) Q4 Earnings: A Look at Key Metrics
07:31pm, Wednesday, 28'th Feb 2024
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
04:05pm, Wednesday, 28'th Feb 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported its financial results for the fourth quarter and year ended December 31, 2023. Rec
Natera: Squeezing The Last Drop From NIPT Growth Engine
07:55pm, Wednesday, 27'th Dec 2023
Natera is a leading company in the field of molecular diagnostics, capitalizing on the growing potential and widespread application in modern healthcare. The company has a proven track record and esta
Natera: Cash Burn Remains A Concern
02:17pm, Wednesday, 25'th Oct 2023
Today, we circle back on Natera, Inc., a fast-growing diagnostic testing concern. The company continues to rack up impressive sales growth, but its cash burn remains a primary concern. With Natera, In
Why Natera Stock Is Soaring Today
11:15am, Friday, 04'th Aug 2023
Natera beat consensus revenue and earnings estimates for the second quarter. The company also raised its full-year revenue guidance.
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
07:31pm, Thursday, 03'rd Aug 2023
Natera (NTRA) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $1.50 per share a year ago.
